BackIVERIC bio Overview

IVERIC bio Current Cash

Track IVERIC bio's current cash ($470M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$467.57M
↑ 143.70% YoYΔ $275.70M vs prior year quarter

Peer average

Loading

IVERIC bio Current Cash History

Loading

IVERIC bio vs. peers: Current Cash Comparison

Loading

IVERIC bio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

IVERIC bio (ISEE) FAQ

IVERIC bio (ISEE) currently reports a current cash of $470M as of March 2023. That compares with $190M in the prior-year period — up 143.7% year over year. Use the charts on this page to explore IVERIC bio's current cash history and peer comparisons.

IVERIC bio's current cash increased from $190M to $470M — a 143.7% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

IVERIC bio reported $470M in current cash as of March 2023. That compares with $190M in the prior-year period — up 143.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $470M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for IVERIC bio, and consider following ISEE for alerts when major investors trade the stock.

IVERIC bio is classified in the Healthcare sector. On current cash, it currently shows $470M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ISEE with unrelated industries.